Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Gilead Sciences easily beat third-quarter forecasts late Wednesday, and raised its outlook in a move that could bolster ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Joseph Stringer’s rating is based on a combination of factors including Gilead Sciences’ recent financial performance and future growth potential. The company reported strong third-quarter results ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

There are a whole host of reasons why Ireland has historically succeeded in attracting more than 90 biopharma companies to ...

A man in his 30s has died in a road crash in Co Cork. The man, who was travelling alone, died after his car is believed to have hit a ditch and crashed into a river on the R571 at Eyeries in west ...

Explore the breadth of our life sciences degrees, spanning the full breadth of life sciences from molecules through to ecosystems. Learn more about the expertise of our research labs where we deliver ...

STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.